Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071006
Status:
COMPLETED
Last Update Posted:
2012-06-08
First Post:
2003-10-09
Brief Title:
AG-013736 Axitinib In Patients With Poor Prognosis Acute Myeloid Leukemia AML Or Myelodysplastic Syndrome MDS
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 2 Study Of AG-013736 In Patients With Poor Prognosis Acute Myeloid Leukemia AML Or Myelodysplastic Syndrome MDS
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome The study tests patients who have poor prognosis before entering the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None